ArticleCancer reports (Hoboken, N.J.)2025
Co-Expression of MHC-II and ANXA1: Mediators of PD-1/PD-L1 Therapy Resistance in Breast Cancer.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterization of ANXA1 in chemotherapy resistance of head and neck squamous cell carcinoma: insights from artificial intelligence and integrative bioinformatics analysis.Frontiers in cell and developmental biology · 2026Article
- Co-Expression of MHC-II and ANXA1: Mediators of PD-1/PD-L1 Therapy Resistance in Breast Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) presents significant treatment challenges and poor prognosis. While immune checkpoint blockade (ICB) therapy shows promise, patient responses vary widely, highlighting the urgent need for reliable biomarkers to predict efficacy and guide treatment decisions.
aimsThis study aims to investigate the role of Major Histocompatibility Complex class II (MHC-II) expression in breast cancer, specifically focusing on its impact on immune evasion, tumor metastasis, and immunotherapy efficacy. The objective is to emphasize the necessity of targeted research in order to enhance therapeutic strategies for TNBC.
methodsWe employed Limma for conducting differential expression analysis, clusterProfiler for performing GO and KEGG pathway enrichment analyses, and Mendelian randomization analyses utilizing data from the UK Biobank and GEO data sets. Single-cell sequencing data were analyzed using Scanpy and CellTypist, where UMAP, PCA, and the Leiden algorithm were applied to explore cellular heterogeneity as well as gene expression profiles.
resultsWe observed significant differential gene expression between MHC-II-high and MHC-II-low hematopoietic stem cells, which has an impact on immune responses and cancer pathways, particularly in TNBC. Mendelian randomization analysis identified key genes associated with breast cancer risk and PD-L1 status. Additionally, ANXA1 was significantly decreased in expression in breast cancer tissues compared to normal tissues and demonstrated increased expression in nonresponders to PD-1/PD-L1 therapies in TNBC patients, suggesting its potential involvement in immunotherapy resistance despite lacking a direct correlation with overall survival rates.
conclusionThe findings of this study highlight the potential role of ANXA1 in mediating resistance to PD-1/PD-L1 therapy in breast cancer, which is associated with MHC-II expression. ANXA1 could serve as both a predictive marker for treatment resistance and a therapeutic target to enhance the efficacy of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.